1. Home
  2. HIW vs ARQT Comparison

HIW vs ARQT Comparison

Compare HIW & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HIW

Highwoods Properties Inc.

HOLD

Current Price

$30.61

Market Cap

3.4B

Sector

Real Estate

ML Signal

HOLD

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$31.43

Market Cap

3.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HIW
ARQT
Founded
1978
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.2B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
HIW
ARQT
Price
$30.61
$31.43
Analyst Decision
Hold
Buy
Analyst Count
10
8
Target Price
$31.89
★ $38.38
AVG Volume (30 Days)
1.1M
★ 2.2M
Earning Date
10-27-2026
11-04-2026
Dividend Yield
★ 6.56%
N/A
EPS Growth
54.26
★ 88.79
EPS
★ 0.29
0.03
Revenue
★ $806,112,000.00
$376,072,000.00
Revenue This Year
$6.94
$43.01
Revenue Next Year
$3.56
$27.70
P/E Ratio
★ $105.16
$1,071.67
Revenue Growth
N/A
★ 91.34
52 Week Low
$20.45
$19.30
52 Week High
$35.44
$33.30

Technical Indicators

Market Signals
Indicator
HIW
ARQT
Relative Strength Index (RSI) 57.20 65.74
Support Level $30.11 $23.42
Resistance Level $30.79 N/A
Average True Range (ATR) 0.86 1.58
MACD 0.20 0.61
Stochastic Oscillator 92.98 80.56

Price Performance

Historical Comparison
HIW
ARQT

About HIW Highwoods Properties Inc.

Highwoods Properties Inc is a fully integrated office REIT that owns, develops, acquires, leases, and manages office properties mainly in the best business districts of Atlanta, Charlotte, Dallas, Nashville, Orlando, Raleigh, Richmond, and Tampa. Its principal business is the operation, acquisition, and development of rental office properties, with no material inter-segment transactions. The Company evaluates performance by geographic location, and the operating results by geographic grouping are regularly reviewed by the chief operating decision maker. The core portfolio consists mainly of office properties in its key markets, with the majority of revenue derived from its Raleigh properties.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Share on Social Networks: